Browse Items (1 total)

Tags: response to therapy

Sort by:

Phase II study of gefitinib in patients with advanced salivary gland cancers.

BACKGROUND: The purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. METHODS: We conducted a phase II study in…

Tags: 2015, 80 and over, Adenocarcinoma/drug therapy/mortality/pathology, adenoid cystic carcinoma, Adenoid Cystic/*drug therapy/mortality/pathology, Adult, Aged, Antineoplastic Agents/*therapeutic use, Blumenschein George R Jr, Carcinoma, Department of Internal Medicine, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, El-Naggar Adel K, Female, Gefitinib, Glisson Bonnie S, Gonzalez-Angulo Ana M, Head & neck, Humans, Jakob John A, Kies Merrill S, Kupferman Michael E, Lee J Jack, Liu Diane D, Local/*drug therapy/mortality/pathology, Male, Maximum Tolerated Dose, Middle Aged, NEOMED College of Medicine, Neoplasm Invasiveness/pathology, Neoplasm Recurrence, Neoplasm Staging, non-adenoid cystic carcinoma, Prognosis, Quinazolines/*therapeutic use, Remission Induction, response to therapy, salivary gland cancer, Salivary Gland Neoplasms/*drug therapy/mortality/pathology, Survival Analysis, Treatment Outcome

Output Formats

atom, dcmes-xml, json, omeka-xml, rss2